Anthera Pharmaceuticals ainitiates BRIGHT-SC Phase 2 clinical study

Anthera Pharmaceuticals announced it has initiated the BRIGHT-SC Phase 2 study of blisibimod, a novel inhibitor of B-Cell Activating Factor for the treatment of IgA nephropathy. IgA nephropathy is a chronic autoimmune renal disease characterized by proteinuria and progression to end stage renal disease. The company plans to conduct an interim analysis of proteinuria after patients have completed 8 weeks of therapy. Secondary endpoints will include the effects of blisibimod on estimated Glomerular Filtration Rate, plasma B cells, and other biomarkers of kidney disease.

View Comments (1)